Servier will produce branded drugs in Vietnam

For the first time, Servier's original branded drug will be "Made in Vietnam"

On May 27, at the French Embassy ( Hanoi ), Servier and Ampharco Pharmaceutical Joint Stock Company signed a technology transfer agreement - marking Vietnam becoming the place to produce a series of strategic generic drugs of Servier. This is a group of high-value drugs, often used in the treatment of chronic diseases such as diabetes, coronary artery disease and venous insufficiency.

According to the agreement, the factory will be located in the Ho Chi Minh City High-Tech Park, invested and built by Ampharco. This factory has just achieved EU-GMP certification in March 2025, allowing the production of drugs that meet the highest European standards. With technical support and supervision from Servier, the factory will start production in 2026 with a scale of about 50% of the total amount of Servier original drugs distributed in the Vietnamese market.

Servier - France's leading independent pharmaceutical group transfers technology to produce generic drugs to Ampharco.

The first product is expected to complete registration procedures and be available on the market by the end of 2026, after a phase of testing, clinical evaluation and marketing authorization. This will be the first time that a generic drug belonging to the group of drugs for the treatment of cardiovascular disease, diabetes and venous insufficiency of Servier is produced in Vietnam.

It is not uncommon for an international pharmaceutical corporation to choose Vietnam as a place to produce generic drugs. According to Mr. Serge Nicollerat, General Director of Servier Vietnam, this is the result of a 7-year cooperation process, based on trust in domestic production capacity, stable policies and the development strategy of the pharmaceutical industry in Vietnam.

Not just a mere processing, this agreement is a real transfer - from technology, production process, quality management to technical team training. Ampharco is not only a manufacturing partner, but also plays the role of an operating unit, controlling the entire chain under international standards.

According to Ampharco representative, with production capacity meeting EU-GMP standards, the factory not only serves the domestic market but also aims to export to Southeast Asian countries in the near future. Producing original drugs locally also helps significantly reduce logistics, import and storage costs, thereby creating conditions for Vietnamese patients to access high-quality drugs at reasonable prices.

In line with the national strategy to 2045

The strategy for developing the Vietnamese pharmaceutical industry to 2030, with a vision to 2045, aims to build Vietnam into a regional pharmaceutical innovation center, with the proportion of domestically produced drugs reaching 80%, including at least 100 original brand-name drugs with production technology transferred.

Ampharco with EU-GMP certification meets the highest pharmaceutical manufacturing standards applied in Europe.

According to statistics from the Ministry of Health , Vietnam currently has about 250 pharmaceutical factories, but only a small portion of them meet EU-GMP standards - a necessary condition to receive technology to produce original pharmaceuticals. Ampharco is one of the few enterprises that meet this requirement, thanks to its thorough investment in infrastructure, human resources and strict adherence to international quality processes.

Servier's choice of Vietnam is not only strategic for its business, but also reflects a positive signal about the investment environment, industrial capacity and stable policy commitment from the Government . This is an opportunity for Vietnam to affirm its position in the global pharmaceutical supply chain, while creating momentum to attract more multinational corporations to shift their investment to the region.

Importantly, the production of original drugs in Vietnam brings direct benefits to patients. Instead of having to access imported drugs, patients can use drugs that meet European standards right in the country, at a reasonable cost and with a more stable supply.

In addition, with quality control according to EU-GMP standards and strict supervision from Servier, products manufactured in Vietnam still ensure quality equivalent to products in Europe, creating greater trust in domestic drugs.

Servier's production of generic drugs in Vietnam is a testament to a new phase in the Vietnamese pharmaceutical industry - from "consumer" to "technology owner".

When international corporations no longer only sell products in Vietnam, but also transfer knowledge, technology and operational capacity, the benefits will not only be for businesses but will spread to the people, the healthcare system and the sustainable development of the Vietnamese pharmaceutical industry.

Source: https://dantri.com.vn/suc-khoe/servier-se-san-xuat-thuoc-biet-duoc-tai-viet-nam-20250605163150490.htm